Related Experiment Video
Updated: Sep 17, 2025

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
Published on: September 18, 2016
Design and Synthesis of Novel sEH Inhibitors for the Treatment of Inflammatory Bowel Disease
Huashen Xu1, Ruolin Cao1, Xinyue Dong2
1Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Abstract:
The treatment of inflammatory bowel disease (IBD) may rely on the comprehensive regulation of immune inflammatory factors to reach a favorable therapeutic effect. In the current study, we discovered a series of sEH inhibitors containing a squaryl sulfonamide scaffold that potently inhibited the primary proinflammatory signaling pathways of NF-κB. Especially, lead compounds A1 and A9 showed potent inhibitory activities against sEH (A1 and A9; hsEH IC50 = 0.1 nM, msEH IC50 = 0.1 nM). The compound A1 had medium pharmacokinetic characteristics in rats. In vivo, A1 showed a strong anti-inflammatory activity in acute enteritis models and decreased the release of various proinflammatory factors, including IL-6 and TNF-α. More importantly, A1 maintained the integrity of the intestinal barrier. Besides, A1 possessed good in vivo tolerability in subacute safety evaluation. Collectively, this study provided valuable lead compounds for the treatment of IBD that were worthy of further development.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:

